Related Experiment Video
Updated: Jan 15, 2026
Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages
Published on: June 23, 2013
Six Interferon-Stimulated Genes as Biomarkers of M1 Macrophage Polarization in Psoriasis
1Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan, People's Republic of China.
Background:
Psoriasis is a chronic, immune-mediated, inflammatory skin disease characterized by abnormal keratinocyte proliferation, in which M1 macrophage polarization plays a critical role. However, the specific biomarkers and mechanisms underlying macrophage polarization in psoriasis remain unclear.
Methods:
We analyzed the psoriasis dataset (GSE14905) to identify differentially expressed genes and applied weighted gene co-expression network analysis to identify key module genes. Macrophage polarization-related (MPR) genes were extracted from the Rummagene database, and MPR genes in psoriasis were identified through Venn analysis. Functional enrichment analysis (GO/KEGG) revealed associated pathways, while six CytoHubba algorithms determined hub genes, with diagnostic potential assessed via ROC curves. Single-gene GSEA further explored biological functions, and single-cell sequencing analysis was performed. Finally, the expression of hub genes and M1 macrophage markers (CD80/CD86) was experimentally validated in psoriasis mouse models.
Results:
Six hub genes (ISG15, RSAD2, IFIT3, OASL, GBP1, and IFIT1) were identified through cytoHubba algorithms. Functional enrichment analysis revealed significant associations between psoriasis-associated macrophage polarization and the RIG-I-like receptor, NOD-like receptor, and cAMP signaling pathways. Experimental validation verified the increased expression of these hub genes and M1 macrophage markers in LPS-stimulated RAW264.7 murine macrophages and IMQ-induced psoriasis animal models.
Conclusion:
Our findings suggest that six interferon-responsive genes (ISG15, RSAD2, IFIT3, OASL, GBP1, and IFIT1) could serve as potential biomarkers for M1 macrophage polarization in psoriasis. Targeting macrophage polarization through IFN pathway inhibition may offer novel therapeutic strategies, particularly for patients with prominent IFN signatures refractory to conventional treatments.
Insights
Six interferon-responsive genes show potential as biomarkers for M1 macrophage polarization in psoriasis. Targeting this pathway may offer new psoriasis treatment strategies, especially for treatment-resistant cases.
Area of Science:
- Immunology
- Dermatology
- Genetics
Background:
- Psoriasis is a chronic inflammatory skin disease driven by abnormal keratinocyte proliferation.
- M1 macrophage polarization is crucial in psoriasis pathogenesis, but its specific biomarkers and mechanisms are not well understood.
Purpose of the Study:
- To identify key genes and pathways involved in M1 macrophage polarization in psoriasis.
- To explore potential biomarkers and therapeutic targets for psoriasis.
Main Methods:
- Analyzed psoriasis gene expression datasets (GSE14905).
- Utilized weighted gene co-expression network analysis and Venn analysis to identify key macrophage polarization-related genes.
- Performed functional enrichment analysis (GO/KEGG), CytoHubba algorithm for hub gene identification, ROC curve analysis, and single-cell sequencing.
- Validated hub gene and M1 macrophage marker expression in cell and animal models.
Main Results:
- Identified six hub genes: ISG15, RSAD2, IFIT3, OASL, GBP1, and IFIT1.
- Found significant associations between psoriasis macrophage polarization and RIG-I-like receptor, NOD-like receptor, and cAMP signaling pathways.
- Confirmed increased expression of hub genes and M1 markers (CD80/CD86) in stimulated macrophages and psoriasis models.
Conclusions:
- The six identified interferon-responsive genes may serve as potential biomarkers for M1 macrophage polarization in psoriasis.
- Inhibiting the IFN pathway could be a novel therapeutic strategy for psoriasis, particularly for patients unresponsive to standard treatments.
